Skip to main content

Advertisement

SpringerLink
Log in

Novel therapeutic approaches in pediatric and young adult sarcomas

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Novel therapy as part of sarcoma treatment schemas can enhance quality of life and is important in improving outcomes of high-risk sarcomas. Additional chemotherapy and biotherapy options to reduce tumor burden and prevent metastases include intra-arterial chemotherapy in osteosarcoma; intrapleural chemotherapy, aerosol 9-nitrocamptothecin, or protracted irinotecan and temozolomide in Ewing’s sarcoma; continuous hyperthermic peritoneal perfusion for malignancy involving the peritoneum, such as desmoplastic small round cell tumor; and ifosfamide with muramyl tripeptide phosphatidyl ethanolamine liposomes in osteosarcoma. These treatments bring improved control of symptoms, including reduction in nausea, mucositis, cardiotoxicity, and central nervous system toxicity. Portable infusion devices have facilitated introduction of outpatient doxorubicin, ifosfamide, and methotrexate regimens and home-infusion irinotecan. Physical approaches to eliminate sarcoma tumors and metastases are critical for durable responses. Novel local control measures include embolization before surgery, radiosensitization, anti-vascular endothelial growth factor therapy during chemo-radiotherapy, proton therapy, samarium, thermal ablation (radiofrequency ablation), and cryoablation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Noguera R: Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. Semin Diagn Pathol 1996, 13(3):171–183.

    PubMed  CAS  Google Scholar 

  2. Sandberg AA: Cytogenetics and molecular genetics of bone and soft-tissue tumors. Am J Med Genet 2002, 115:189–193.

    Article  PubMed  Google Scholar 

  3. Hoglund M, Gisselsson D, Mandahl N, Mitelman F: Ewing tumours and synovial sarcomas have critical features of karyotype evolution in common with epithelial tumours. Int J Cancer 2005, 116:401–406.

    Article  PubMed  CAS  Google Scholar 

  4. Mandahl N, Mertens F, Panagopoulos I, Knuutila S: Genetic characterization of bone and soft tissue tumors. Acta Orthop Scand Suppl 2004, 75:21–28.

    PubMed  CAS  Google Scholar 

  5. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 2005, 27:215–218.

    Article  PubMed  Google Scholar 

  6. Anderson P: Osteosarcoma relapse: Expect the worst, but hope for the best. Pediatr Blood Cancer 2005. [Epub ahead of print] The author offers a perspective on relapse in osteosarcoma, indicating that local control is still important.

  7. Kager L, Zoubek A, Potschger Um, et al.: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003, 21:2011–2018.

    Article  PubMed  Google Scholar 

  8. Hesketh PJ, Batchelor D, Golant M, et al.: Chemotherapyinduced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004, 12:543–549.

    PubMed  Google Scholar 

  9. Oo TH, Hesketh PJ: Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2005, 2:196–201.

    Article  PubMed  CAS  Google Scholar 

  10. Sharma R, Tobin P, Clarke SJ: Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005, 6:93–102.

    Article  PubMed  CAS  Google Scholar 

  11. Foubert J, Vaessen G: Nausea: the neglected symptom? Eur J Oncol Nurs 2005, 9:21–32.

    Article  PubMed  Google Scholar 

  12. Behl D, Porrata LF, Markovic SN, et al: Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006, 20:29–34.

    Article  PubMed  CAS  Google Scholar 

  13. Yoong Y, Porrata LF, Inwards DJ, et al.: The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin’s lymphoma. Leuk Lymphoma 2005, 46:1287–1294.

    Article  PubMed  Google Scholar 

  14. Porrata LF, Gastineau DA, Padley D, et al.: Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003, 44:997–1000.

    Article  PubMed  CAS  Google Scholar 

  15. Grimble RF: Immunonutrition. Curr Opin Gastroenterol 2005, 21(2):216–222.

    Article  PubMed  CAS  Google Scholar 

  16. Fuchs BC, Bode BP: Stressing out over survival: glutamine as an apoptotic modulator. J Surg Res 2006, 131:26–40.

    Article  PubMed  CAS  Google Scholar 

  17. Gatti L, Zunino F: Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 2005, 111:127–148.

    PubMed  CAS  Google Scholar 

  18. Roth E, Oehler R, Manhart N et al.: Regulative potential of glutamine--relation to glutathione metabolism. Nutrition 2002, 18:217–221.

    Article  PubMed  CAS  Google Scholar 

  19. Plauth M, Raible A, Vieillard-Baron D, et al.: Is glutamine essential for the maintenance of intestinal function? A study in the isolated perfused rat small intestine. Int J Colorectal Dis 1999, 14:86–94.

    Article  PubMed  CAS  Google Scholar 

  20. Anderson PM, Schroeder G, Skubitz KM: Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998, 83:1433–1439.

    Article  PubMed  CAS  Google Scholar 

  21. DeLaney TF, Park L, Goldberg SI, et al.: Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005, 61:492–498.

    Article  PubMed  Google Scholar 

  22. Machak GN, Tkachev SI, Solovyev YN, et al.: Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 2003, 78:147–155.

    Article  PubMed  Google Scholar 

  23. Ahrar K: The role and limitations of radiofrequency ablation in treatment of bone and soft tissue tumors. Curr Oncol Rep 2004, 6:315–320.

    PubMed  Google Scholar 

  24. Wang H, Littrup PJ, Duan Y, et al.: Thoracic masses treated with percutaneous cryotherapy: initial experience with more than 200 procedures. Radiology 2005, 235:289–298.

    Article  PubMed  Google Scholar 

  25. Wagner LM, Crews KR, Iacono LC et al.: Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004, 10:840–848. The authors describe a non-cross-resistant regimen with activity in pediatric (small blue cell) sarcomas. This regimen is the basis for current COG ADVL0414 and L9NC+ temozolomide studies.

    Article  PubMed  CAS  Google Scholar 

  26. Chugh R, Dunn R, Zalupski MM, et al.: Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005, 23:3597–3604.

    Article  PubMed  CAS  Google Scholar 

  27. Sugarbaker PH: A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 2005, 32(Suppl 9):68–73.

    Article  Google Scholar 

  28. Sugarbaker PH, Stuart OA, Yoo D: Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy. J Oncol Pharm Pract 2005, 11:111–119.

    Article  PubMed  Google Scholar 

  29. Sugarbaker PH: Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy. Tech Coloproctol 2005, 9:95–103.

    Article  PubMed  CAS  Google Scholar 

  30. Gil A, Gomez Portilla A, Brun EA, Sugarbaker PH: Clinical perspective on desmoplastic small round-cell tumor. Oncology 2004, 67:231–242.

    Article  PubMed  Google Scholar 

  31. Kasper B, Ho AD, Egerer G: A new therapeutic approach in patients with advanced sarcoma. Int J Clin Oncol 2005, 10:438–440.

    Article  PubMed  CAS  Google Scholar 

  32. Eilber FC, Tap WD, Nelson SD, et al.: Advances in chemotherapy for patients with extremity soft tissue sarcoma. Orthop Clin North Am 2006, 3:15–22.

    Article  Google Scholar 

  33. Meyers PA, Schwartz CL, Krailo M, et al.: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005, 23:2004–2011.

    Article  PubMed  CAS  Google Scholar 

  34. Komdeur R, Meijer C, Van Zweeden M, et al.: Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol 2004, 25:677–684.

    PubMed  CAS  Google Scholar 

  35. Maurel J, Fra J, Lopez-Pousa A, et al.: Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 2004, 100:1498–1506.

    Article  PubMed  CAS  Google Scholar 

  36. Lipshultz SE, Giantris AL, Lipsitz SR, et al.: Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002, 20:1677–1682.

    Article  PubMed  CAS  Google Scholar 

  37. D’Adamo DR, Anderson SE, Albritton K, et al.: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005, 23:7135–7142.

    Article  PubMed  CAS  Google Scholar 

  38. Wood LS: Liposomal anthracycline administration and toxicity management: a nursing perspective. Semin Oncol 2004, 31(Suppl 13):182–190.

    Article  PubMed  CAS  Google Scholar 

  39. Abraham SA, Waterhouse DN, Mayer LD, et al.: The liposomal formulation of doxorubicin. Methods Enzymol 2005, 391:71–97.

    Article  PubMed  CAS  Google Scholar 

  40. O’Brien ME, Wigler N, Inbar M, et al.: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440–449.

    Article  PubMed  CAS  Google Scholar 

  41. Laginha KM, Verwoert S, Charrois GJ, Allen TM: Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005, 11:6944–6949. These authors provide direct evidence showing increased tumor penetration of liposomal doxorubicin compared with free doxorubicin. If this drug works better and does not cause alopecia, why is it not used more often in pediatric sarcoma treatment?

    Article  PubMed  CAS  Google Scholar 

  42. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145–147.

    Article  PubMed  CAS  Google Scholar 

  43. Gorski DH, Beckett MA, Jaskowiak NT, et al.: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374–3378.

    PubMed  CAS  Google Scholar 

  44. Tong RT, Boucher Y, Kozin SV, et al.: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731–3736.

    Article  PubMed  CAS  Google Scholar 

  45. Skubitz KM, Hamdan H, Thompson RCJr: Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 1993, 72:2963–2969.

    Article  PubMed  CAS  Google Scholar 

  46. Boyer MW, Moertel CL, Priest JR, Woods WG: Use of intracavitary cisplatin for the treatment of childhood solid tumors in the chest or abdominal cavity. J Clin Oncol 1995, 13(3):631–636.

    PubMed  CAS  Google Scholar 

  47. Anderson PM, Markovic SN, Sloan JA, et al.: Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999, 5:2316–2323.

    PubMed  CAS  Google Scholar 

  48. Goetz MP, Callstrom MR, Charboneau JW, et al.: Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004, 22:300–306.

    Article  PubMed  Google Scholar 

  49. Ahmed M, Liu Z, Lukyanov AN, et al.: Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005, 235:469–477.

    Article  PubMed  Google Scholar 

  50. Anderson PM, Wiseman GA, Erlandson L, et al.: Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005, 11:6895–6900.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, 77030-4009, Houston, TX, USA

    Peter M. Anderson MD, PhD

Authors
  1. Peter M. Anderson MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret Pearson RN, MSN, CPNP, CPON
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter M. Anderson MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderson, P.M., Pearson, M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 8, 310–315 (2006). https://doi.org/10.1007/s11912-006-0038-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0038-0

Keywords

Search

Navigation